HIF-1α signaling: Essential roles in tumorigenesis and implications in targeted therapies.

Introduction

Recently, it has been identified that hypoxia-inducible factor-1 alpha (HIF-1α) is a major transcriptional regulatory factor that responds to hypoxic environments and modulates the expression of many genes in the organism and is closely associated with the biological behavior of malignant tumors. 1 , 2 Importantly, HIF-1α is commonly highly expressed in tumors under conditions of hypoxia or activation of oncogenic pathways. Further studies revealed that HIF-1α not only participates in reducing the efficacy of radiotherapy, chemotherapy, and targeted therapies but also its target genes are involved in a multitude of pathophysiological mechanisms, such as regulation of angiogenesis, cell proliferation and survival, glucose metabolism, immune escape, and iron metabolism. 2 , 3 Therefore, HIF-1α has been recognized to play an important role in diseases that can generate a hypoxic environment ( e.g. , malignancies).

In the process of carcinogenesis, normal cells in the organism gradually evolve into malignant lesions, and these lesions can ultimately result in the development of a local malignancy followed by distant metastasis. 4 For example, malignancy occurs when normal cells acquire a transforming mutation in cancer driver genes through a genetic or sporadic event. 4 Among them, hematological malignancies are a group of heterogeneous diseases that are related to hematopoietic and lymphoid tissues and are the fourth most prevalent cancer. 5 The etiology is not yet clear, but most scholars believe that their occurrence is linked to genetics, 6 environment, chemicals, and infections. Strikingly, the occurrence of malignancies exerts a serious impact on the safety of lives and quality of life for patients, especially leading to a poor prognosis for elderly and frail patients. Currently, their treatment regimens include surgery, radiotherapy, chemotherapy, immunotherapy, hematopoietic stem cell transplantation (HSCT), etc . 7 , 8 , 9 However, in a significant proportion of patients, clinical outcomes remain quite poor owing to drug resistance to cancer treatment or relapse of the disease. Consequently, the urgent need to elucidate the pathogenesis with a view to discovering new targets is of high importance.

At present, it is widely recognized that the microenvironment in which solid tumors commonly grow is hypoxia. 10 Indeed, malignant tumors are a serious threat to human health and the hypoxic microenvironment (HME) is tightly correlated with the malignant progression of tumors ( e.g. , tumor growth, angiogenesis) with complex regulatory mechanisms. HIF-1α is essential for tumor cells to adapt to the HME. Recent evidence confirms that, with the exception of solid tumors such as breast and liver cancer, HIF-1α is also strongly associated with the development and progression as well as chemotherapy resistance and tumor metastasis of hematological malignancies ( e.g. , acute myeloid leukemia (AML)). 11 In this review, we briefly outline the basic structure and biological functions of HIF-1α and discuss the progress of research on HIF-1α in multiple solid tumors and hematological malignancies. Collectively, translational therapy with targeted interventions targeting HIF-1α may provide novel insights for the future precision treatment of malignancies.

Overview of hypoxia-inducible factors (HIFs)

In a recent study, Semenza et al 12 unveiled the molecular mechanisms underlying the “discovery of how cells sense and adapt to changes in oxygen”. Subsequently, they were awarded the 2019 Nobel Prize in Physiology or Medicine in recognition of their contribution to a deeper understanding of how oxygen levels affect cellular metabolism and the function of physiology. Further, relevant research on the molecular mechanism has proven to be influential in the treatment of diverse human diseases, including anemia and cancer. 12 In this regard, HIF-1 is a transcription factor related to the regulation of cellular adaptation to the hypoxic environment identified by Semenza et al 13 during hypoxia induction in hepatocellular carcinoma (HCC) cell lines.

HIFs, a family of transcription factors, are key regulatory factors involved in the modulation of the cellular response to hypoxic stress. 14 Among them, it is currently reported that the most important proteins activated in hypoxia are three HIFs, i.e. , HIF-1, HIF-2, and HIF-3. 15 To our knowledge, the first two, HIF-1 and HIF-2, are mainly accountable for the transcription of relevant genes triggered by hypoxia, whereas HIF-3, aside from inducing the expression of target genes, also negatively regulates the activity of HIF-1 and HIF-2, thereby indirectly inhibiting the expression of oncogenes. 16 , 17 , 18

All three HIFs are constituted by two subunits, a heterodimer formed by the oxygen-sensitive α-subunit and the oxygen-insensitive β-subunit. 15 To date, three isoforms of α-subunits for HIF have been identified in humans or mammals, including HIF-1α, -2α, and -3α. Specifically, HIF-1α is the most thoroughly studied isoform and is commonly expressed in human cells; HIF-2α is only expressed in specific tissues and cell types such as lung, kidney, and liver; and HIF-3α is mainly expressed in heart, kidney, and lung epithelial cells. 19 Furthermore, the HIF-1β subunits, also known as the aryl hydrocarbon receptor nuclear translocator (ARNT), are encoded by two genes, ARNT1 and ARNT2. 20 , 21 Reyes et al 22 revealed that HIF-1β is stably expressed in humans and is also a specialized chaperone of the aryl hydrocarbon receptor (AHR) ( Fig. 1 ). Figure 1 HIF protein domains. Currently, three oxygen-sensitive α-subunit isoforms of HIF have been identified in humans (HIF-1α, -2α, and -3α) and form heterodimers with the oxygen-insensitive β-subunit (also known as the aryl hydrocarbon receptor nuclear translocator (ARNT)). The HIF protein consists of several conserved domains, including a DNA-binding (basic Helix-Loop-Helix, bHLH) domain, a protein/protein interaction and dimerization (PER-ARNT-SIM, PAS-A and PAS-B) domain, an oxygen-dependent degradation domain (ODDD), a transcriptional activation domain (N-TAD, C-TAD), and a repressive domain (ID). ARNT, aryl-hydrocarbon-nuclear receptor translocator; CBP, cyclic adenosine monophosphate response element-binding protein; FIH1, factor-inhibiting HIF-1; HIF-1α, hypoxia-inducible factor-1 alpha; p300, coactivator acetyltransferase; PHD, proline hydroxylase domain; pVHL, von Hippel-Lindau tumor suppressor protein. Fig. 1

The basic structure of HIF-1α

HIF-1 belongs to an oxygen-dependent transcriptional activator widely present in human and mammalian cells and is a heterodimer composed of an α subunit (HIF-1α) and a β subunit (HIF-1β) that contributes to the progression of tumors and mammalian development. 23 Among them, the β-subunit is a structural subunit that is continuously expressed in the nucleus independently of oxygen concentration, as compared to the α-subunit, which is a functional subunit that responds differently to hypoxia and normoxia and is the main site of HIF-1 in tumorigenesis. 3 , 23

Both HIF-1α and HIF-β are classified as members of the basic helix-loop-helix (bHLH)-PAS (PER-ARNT-SIM, PAS) family of structural domain transcription factors, which contain a bHLH domain and two PAS domains (PAS-A and PAS-B). 24 , 25 Typically, the HLH and PAS domains facilitate heterodimerization between HIF-1α and HIF-β, while the basic region preceding the N-terminal end of the HLH domain is responsible for the binding of the HIF-1α/HIF-β heterodimer to the DNA motifs of the hypoxia response elements (HREs) on the promoter of HIF-1 target genes. 26 , 27

In addition, HIF-1α also possesses other critical structural domains, one of which is the oxygen-dependent degradation domain (ODDD) located at the free carboxyl terminus (C-terminus) of the HIF-1α peptide chain, which functions to rapidly degrade the α-subunit under normoxia 28 ; and two transactivation domains (TAD), respectively near the C-terminus (C-TAD) and the free amino terminus (N-TAD), both of which are required for HIF-1α initiation and stimulation of target genes transcription. 29 Of these, C-TAD can modulate the trans-activation of target genes through the recruitment of CBP/p300 (a transcriptional coactivator). 30 Interestingly, there is also an inhibitory domain (ID) between C-TAD and N-TAD that can decrease the activity of the transcriptional activation domain of HIF-1α.

Under normoxic conditions, it has been confirmed that HIF-1α is predominantly catabolized via the ubiquitin-proteasome pathway in normal cells and is hyperexpressed. 3 Mechanistically, α-ketoglutarate and iron-dependent prolyl hydroxylase (PHD) catalyze the hydroxylation of proline residues ( e.g. , Pro-402 and Pro-564) in the ODDD of HIF-1α 31 , 32 , 33 ; concurrently, the Lys residue at position 532 is acetylated by acetyltransferase-1 (ARD-1). The residue is subsequently recognized by the Von-Hippel-Lindau (VHL) E3 ubiquitin ligase complex, leading to ubiquitination of the HIF-1α subunit and eventual degradation by the 26S proteasome, which indicates a negative regulatory effect of PHD on HIF-1α transcription. 33 , 34 Moreover, the transcriptional activity of HIF, which escapes degradation, is controlled by the factor inhibiting HIF (FIH), an oxygen-dependent enzyme with asparagine hydroxylase activity towards the HIF-α subunit. 35 The oxygen-dependent hydroxylation of asparagine residues ( e.g. , Asn-803) disrupts the interaction between CBP/p300 and HIF-1α via FIH, thereby inhibiting its transcriptional activity. 31 , 35 , 36 In contrast, PHD and FIH are inactive under hypoxic conditions and the asparagine and prolyl in the HIF-1α protein fail to be hydroxylated, permitting the accumulation of HIF-1α in the cytoplasm. 30 , 37 Further, the stable HIF-1α subunit is importantly transferred to the nucleus to form a heterodimer with HIF-1β and binds to HREs to activate downstream target genes that are involved in various life processes such as angiogenesis, glucose metabolism, cell proliferation, and survival 31 , 38 , 39 , 40 ( Fig. 2 ). Figure 2 The degradation and activation of HIF-1α. Under normoxic conditions, the key residues of the conserved proline (Pro-402 and Pro-564) in the HIF-1α subunit can be hydroxylated by PHD. Subsequently, the HIF-1α subunit is ubiquitinated by the E3 ubiquitin ligase complex, which contains the Von Hippel-Lindau protein (a negative regulator of HIF-1α transcriptional activity) and is ultimately degraded by the 26S proteasome. Asparagine (Asn-803) is hydroxylated by asparagine hydroxylase, which inhibits the transactivation of HIF-1α and prevents HIF-1α from binding to CBP/p300 (transcriptional co-activator). FIH1 and ROS/NO also affect HIF-1α activity; the former blocks HIF-1α binding to CBP/p300 and inhibits HIF-1α transcriptional activation, and the latter suppresses the acetylation of HIF-1α by impeding the activation of PHD. In contrast, hydroxylation and acetylation of HIF-1α are inhibited under hypoxia. Stable HIF-1α forms a heterodimer with the HIF-1β (ARNT) subunit after translocation to the nucleus, which in turn binds to CBP/p300 and binds to hypoxia-responsive elements (HREs) on the promoter of HIF-1 target genes to constitute a transcription initiation complex, which eventually activates downstream target genes. NO, nitric oxide; ROS, reactive oxygen species. Fig. 2

The functions of HIF-1α

To our knowledge, the expression of HIF-1α is elevated in many types of human cancer cells, and there is a definite correlation between HIF-1α and tumor prognosis. 41 In particular, the experimental data demonstrate that HIF-1α, a key transcription factor for adaptation to hypoxia, can regulate the expression of >100 genes downstream, including four categories of target genes that are inextricably linked to protein production and tumors: vascular endothelial growth factor (VEGF), glucose transport and glycolytic enzymes (GLUT), factors involved in tumor invasion and metastasis, and proteins related to tumor proliferation and apoptosis. 42 Notably, in the process of disease development, these genes, when affected, can modulate the relative homeostasis of the internal environment in tissues and cells under hypoxic conditions. For example, they not only modulate classical biological behaviors that include stem cell maintenance, cell survival, apoptosis, erythropoiesis, and angiogenesis, but also influence the microenvironment and metabolic state of tumors, the energy metabolism of nucleotides, amino acids, and glucose, and participate in immune evasion. Additionally, HIF-1α drastically regulates genes related to drug resistance and other altered responses and therefore acts as a key player in tumorigenesis.

Malignant biological behaviors of HIF-1α in tumorigenesis under hypoxia

The tumor microenvironment (TME) is the complex environment in which tumor cells survive. It contains not only the structure, function, and metabolism of the tumor tissue but also the intrinsic environment (nuclear and cytoplasmic) of the tumor cells themselves. Essentially, the TME is composed of tumor cells, stromal cells, endothelial cells, and immune cells. 43 In the process of tumor occurrence, as well as growth and metastasis, TME plays a crucial role. The rapid proliferation of malignant tumor cells contributes to increased consumption of oxygen, and metastasis in turn results in reduced oxygen delivery, thus creating an HME for tumor formation. In a hypoxic environment, the accumulation of HIF-1α can regulate the expression of downstream genes through multiple mechanisms, facilitating tumor cell proliferation, angiogenesis, energy metabolism, epithelial–mesenchymal transition (EMT), immune escape, etc. , thereby making tumor cells more tolerant of the HME and acquiring greater capabilities for proliferation, metastasis, and invasion 42 , 44 ( Fig. 3 ). Figure 3 Malignant biological behaviors of HIF-1α in tumorigenesis under hypoxia. The tumor microenvironment (TME) is a complex environment in which tumor cells live. The TME plays a crucial role in tumorigenesis, growth, and metastasis. The rapid proliferation of malignant tumor cells contributes to increased consumption of oxygen, while metastasis leads to reduced oxygen delivery, thus creating a hypoxic microenvironment (HME) for tumor formation. In a hypoxic environment, the accumulation of HIF-1α can regulate the expression of downstream genes through a variety of mechanisms, promoting tumor cell proliferation, angiogenesis, energy metabolism, epithelial–mesenchymal transition (EMT), and immune escape, etc. , thereby making tumor cells more tolerant to HME and acquiring the greater capacity for proliferation, metastasis, and invasion. Fig. 3

HIF-1α and the proliferation and apoptosis of tumor cells

In the HME, mounting evidence has indicated that HIF-1α can modulate downstream target genes to promote the proliferation of tumors as well as suppress the apoptosis of tumor cells via interacting with cofactors. 45 , 46 JAG1 (JAG1), a specific ligand for the Notch signaling pathway in mammals, acts in interaction with Notch receptors to activate the Notch pathway, provoking the shedding of the Notch intracellular structural domain (NICD), and binding to cofactors to stimulate the expression of numerous target genes involved in diverse life processes. 47 , 48 More importantly, it has been reported that hypoxia-activated HIF-1α participates in tumor metabolism and angiogenesis, and boosts the proliferation, invasion, and metastasis of tumors by activating the Notch pathway, a key regulatory signaling mechanism that governs the fate of tumor cells and EMT. 49 , 50 Conversely, inhibition of the Notch pathway contributes to further apoptosis of tumor cells. As is widely known, the TP53 gene is primarily responsible for encoding the corresponding tumor suppressor protein, p53, and is the most commonly mutated gene in all human cancers. Indeed, previous reports have declared that wt p53 (wild-type p53, wt p53) negatively regulates the stability of HIF-1α. Thus, Amelio et al 51 showed that the main role of wt p53 is to modulate the cell cycle and accelerate cell death and that the physical binding of HIF-1α to wt p53 facilitates wt p53-mediated hypoxic cell death. In addition, cancer cells are often already exposed to decreased oxygen tension at the stage when mutations in TP53 occur. 52 , 53 Mutant-type p53 (mt p53) can accelerate cell growth via interacting with HIF-1α and is ultimately engaged in the progression of tumors. 51 Furthermore, HIF-1α also inhibits the apoptosis of tumor cells by down-regulating the levels of the anti-apoptotic proteins Bcl2 ( e.g. , IL-6/STAT3/Bcl2 pathway), 54 , 55 an inhibitor of apoptosis protein-2 (IAP-2) 55 and lowering the levels of cleaved caspase-3 and the pro-apoptotic proteins Bcl2 associated X protein (BAX). 56

HIF-1α and energy metabolism in malignant tumors

Specifically, many critical enzymes of the glycolytic pathway are targets of HIF-1α, which is thought to mediate the activation of glycolysis in cancer cells. Under conditions of severe hypoxia, HIF-1α prevents the entry of pyruvate into the tricarboxylic acid cycle and elevated mitochondrial reactive oxygen species (ROS) by activating the PDK1 protein, avoiding a massive increase in ROS to cause apoptosis. 57 Here, Semba et al 57 consider that the metabolic changes are related to the adaptation of tumor cells to a hypoxic environment. In another recent study, the researchers found that up-regulation of HIF-1α in tumor cells is resistant to apoptosis and proliferation hindrance induced by hypoxia and hypoglycemia, while inhibition of HIF-1α expression makes cancer cells more sensitive to apoptosis and proliferation hindrance induced by hypoxia and hypoglycemia. 58 Mechanistically, reduced expression of Glut-1 and aldolase A mRNA and sugar uptake-related proteins in tumor tissues would result in decreased tumorigenicity of in vivo tumor cells. 58 Thus, these results suggest that the effect of HIF-1α on cancer cells relies on alterations in glycolytic metabolism and is a potentially effective way to cure tumors. Pyruvate kinase isozymes M2 (PKM2) is a key regulatory enzyme in glycolysis and was predicted to be a target of transcription factor TEA domain 4 (TEAD4) by Hu et al 59 using bioinformatics analysis. In in vitro experiments on tumor cells, they have confirmed, using a luciferase reporter gene assay, that TEAD4 boosts the transcription and expression of PKM2, which further elevates the activity of HIF-1α and therefore increases the expression of the HIF-1α-targeted glycolytic genes glucose transporter-1 and hexokinase II; conversely, the supplementation of 2-deoxy- d -glucose (2-DG) blocked the positively regulated glycolysis by TEAD4 and PKM2. 59 Furthermore, peroxisome proliferator-activated receptors (PPAR) are ligand-activated nuclear receptors of the steroid/thyroid hormone receptor superfamily. There are three isoforms, α, β/δ, and γ, which are closely associated with lipid storage and mobilization, glucose metabolism, morphogenesis, and inflammatory responses. 60 Among them, the expression of PPAR-γ was known to be modulated by HIF-1α. 61 Simvastatin, a cholesterol-lowering drug, can suppress the HIF-1α/PPAR-γ/PKM2 axis via inhibiting PKM2-mediated glycolysis, leading to reduced proliferation and increased apoptosis in HCC cells and re-sensitizing HCC cells to sorafenib. 62 Collectively, these data provide a theoretical basis for implicating HIF-1α as a poor prognosticator.

HIF-1α and tumor angiogenesis

Malignant tumorigenesis is typically accompanied by a marked hypoxia in the tumor environment, which may be related to insufficient tissue oxygenation due to the excessive growth of tumors and relatively low angiogenesis. However, to the extent that tumor tissue can continue to grow in this hypoxic environment, HIF-1α performs an essential role in the process. Vascular endothelial growth factor (VEGF) acts as a key mediator of angiogenesis, mainly promoting the proliferation, survival, and migration of endothelial cells, and increasing vascular permeability. 63 Some previous studies revealed that HIF-1α has been identified as a major regulator of VEGF expression. In a hypoxic environment, the HIF-1α-p300/CBP complex binds to the HRE sequence in the 5′ promoter region of the VEGF gene, thus triggering the expression of VEGF and neovascularization. 64 Currently, it is widely acknowledged that PIM kinases are oncogenic serine/threonine kinases. 65 Increased expression of PIM1 in vivo can trigger the expression of HIF-1α target genes ( VEGF and HK2 ) by directly phosphorylating HIF-1α at threonine 455, thereby inducing angiogenesis; however, VEGF is notably deficient in HIF-1α-knockdown tumor tissues. 66 Prolactin II (SCG2) is markedly under-expressed in malignant tumor tissues and is correlated with shorter disease-free survival and overall survival in cancer patients. 67 , 68 , 69 In another animal study, SCG2 suppressed the expression of VEGF via interacting with VHL tumor inhibitors in cancer cells, fostering the degradation of HIF-1α; in contrast, the accumulation of HIF-1α could effectively elevate the SCG2-mediated expression of VEGF in cancer cells. 67 Hence, it has been revealed that ectopic expression of SCG2 apparently impeded tumor growth by disrupting angiogenesis.

HIF-1α and tumor immune escape

In the TME, HIF-1α mainly promotes tumor immune escape by regulating a variety of immune cells ( e.g. , T lymphocytes, macrophages, myeloid-derived suppressor cells (MDSCs)). 70 , 71 , 72 Dysregulation of the immune microenvironment and treatment resistance are the dominant causes of cancer. Concretely, the programmed cell death protein 1 (PD-1)/programmed cell death 1 ligand 1 (PD-L1) axis is an integral component of the immunosuppression in the organism. 73 In 2021, Deng et al 73 showed that HIF-1α can result in tumor immune escape by mediating the up-regulation of PD-L1, which in turn leads to disease progression. Furthermore, suppression of the PD-1/PD-L1 axis may alleviate chemoresistance in tumor patients due to the guaranteed survival of CD4 + T cells and CD8 + T cells. 73 Meanwhile, PD-1 has been reported for the first time as a novel downstream molecule of HIF-1α, apart from PD-L1. 74 However, the efficacy of anti-PD-1 therapies for tumors with high HIF-1 levels remains to be explored. Another recent study found that HIF-1α prevents tumor cells from being subjected to immune surveillance with enhanced levels of carbonic anhydrase IX (CA9) expression. 75 More importantly, it is apparent that fenofibrate, a PPAR alpha (PPAR-α)-specific agonist, further represses the expression of hypoxia-induced HIF-1α and CA9 in tumors by activating the AMP-activated protein kinase (AMPK) pathway and SIRT1 in tumor cells using HO-1. 75 Overall, the research into drugs targeting HIF-1α-related immune mechanisms could be of assistance in anti-cancer therapy.

HIF-1α and tumor drug resistance

Under hypoxic conditions, the sensitivity of tumor cells to chemotherapeutic drugs is greatly impaired. HIF-1α and p53 are jointly engaged in anti-cancer drug resistance. The cytotoxicity of anticancer drugs ( e.g. , doxorubicin, gemcitabine, and cisplatin) at 1% oxygen was even lower than that at 5% oxygen, mainly owing to the fact that these drugs increased the expression of 4E-BP1-dependent HIF-1α protein, but did not alter the level of p53. 76 However, when oxygen concentrations were raised, the drugs not only inhibited HIF-1α expression but also enhanced p53 levels, ultimately resulting in massive death of tumor cells. 76 Recently, accumulating evidence reveals that microRNAs (miRNAs) play an influential role in the acquired drug resistance of tumor cells. 54 In in vitro cellular assays, overexpression of HIF-1α reduced the expression of miR-338-5p under both normoxic and hypoxic conditions. Subsequently, the deficiency of miR-338-5p in hypoxic cancer cells moderated the decrease in IL-6 expression and reactivated the anti-apoptotic STAT3/Bcl2 signaling pathway, thus impeding tumor cell death and improving the drug resistance of tumor cells. 54 Taken together, the Yin group here has identified a hypoxia-triggered HIF-1α/miR-338-5p/IL-6 feedback loop, offering a direction for future research in cancer therapy.

The role of HIF-1α in solid tumors

In the hypoxic environment triggered by solid tumors, HIF-1α is stably present and activates the transcription of tumor invasion-related genes, thus fostering tumor progression and chemotherapy resistance. 77 In brief, tissue hypoxia and certain molecular alterations ( e.g. , mutations in oncogenes such as ERBB2 and suppressors such as VHL and PTEN ) contribute to the overexpression of HIF-1α in tumor cells, which in turn leads to tumor metastasis, treatment failure, and high mortality 37 , 78 , 79 , 80 , 81 ( Fig. 4 ). Figure 4 The role of HIF-1α in solid tumors. HCC, hepatocellular carcinoma; NSCLC, non-small-cell lung cancer; EMT, epithelial-to-mesenchymal transition; hCINAP, human coilin-interacting nuclear ATPase protein; MPE, malignant pleural effusion; BEV, bevacizumab; VEGF, vascular endothelial growth factor; PDTC, pyrrolidine dithiocarbamate; APA, apatinib. Fig. 4

It has been reported that HIF-1α is highly expressed in tumors such as breast, liver, bladder, cervical, colorectal, endometrial, lung, etc . 77 NANOG is a protein required for the self-renewal of breast cancer stem cells (BCSCs), and high expression of NANOG in tumor tissues of breast cancer patients is correlated with poor prognosis. 82 Mechanistically, HIF-1α maintains telomere length by recruiting NANOG to activate transcription of the TERT gene (encoding telomerase reverse transcription), ensuring self-renewal in stem cells. In addition, NANOG also binds to the deubiquitinase USP9X to regulate HIF-1α activity and consequently stimulate the rapid growth of tumors and drug resistance through the interaction of HIF-1α with CBP/p300. 82 In HCC, HIF-1α could promote the growth, invasion, metastasis, and development of drug resistance to sorafenib treatment in HCC cells by up-regulating the expression of the target gene RIT1 . 83 Similarly, Feng et al 84 found that HIF-1α was significantly overexpressed in HCC cells and facilitated the migration and invasion of HCC cells by modulating IL-8 via the NF-κB (nuclear factor-kappa B) pathway. Pyrrolidine dithiocarbamate (PDTC), an inhibitor of NF-κB, could block the HIF-1α/IL-8/NF-κB axis and thus inhibit the proliferation of HCC cells. In cervical cancer cells, HIF-1α and HIF-1β facilitate the migration capacity, EMT, and anti-apoptotic effects of cancer cells in response to hypoxia via directly up-regulating the expression of its target gene hCINAP . 85

Owing to the survival of cancer stem cells (CSC), colorectal cancer patients generally suffer recurrence after chemotherapy. Recent studies have confirmed that high expression levels of HIF-1α/TGF-β2/GLI2 are closely associated with relapse after chemotherapy in patients. 86 Inhibition of HIF-1α could effectively reverse chemoresistance induced by the TME by blocking TGF-β2/GLI2 signaling, indicating a potential biomarker and therapeutic target. 86 , 87 In the glioma LN229 cell line, knockdown of HIF-1α inhibited cell invasiveness and increased therapeutic sensitivity by negatively modulating the time-dependent expression of miR-224-3p in hypoxia. 88 Moreover, further studies revealed that hypoxia can increase the relative expression of ATG5 (autophagy-associated gene 5), which is a target of miR-224-3p, suggesting that it induces autophagy in tumor cells, eventually causing them to be less sensitive to chemotherapeutic drugs. 88 Using a mouse xenograft model of non-small cell lung cancer (NSCLC), Xiang et al 89 observed that a triple–drug combination (apatinib + bevacizumab (BEV) + cisplatin) suppressed angiogenesis and the formation of malignant pleural effusion (MPE) in NSCLC by down-regulating HIF-1α, VEGF, VEGFR-2, MEK1, and MMP-2 molecular signaling pathway proteins, and facilitated apoptosis of tumor cells in vivo , ultimately greatly prolonging the overall survival of tumor-bearing mice. Apart from the above, HIF-1α also participated in the proliferation, migration, invasion, and angiogenesis of tumor cells in cholangiocarcinoma. 90

The role of HIF-1α in leukemia

Indeed, studies have confirmed that the oxygen concentration in the bone marrow (BM) is extremely rare, down to 0.6%, and that the hypoxic environment is protective of leukemic stem cells and maintains their ability to self-renew. 91 As is well known, the testis and the central nervous system (CNS) are the most vulnerable sites for extramedullary relapse of acute lymphoblastic leukemia (ALL), and both have a common feature with the BM — a hypoxic environment. Importantly, hypoxia-activated HIF-1α can affect the prognosis of patients with leukemia 91 ( Table 1 ). Table 1 The functional roles of HIF-1α in diverse types of hematological malignancies. Table 1 Cancer type Patients or cell lines Role of HIF-1α in cancer Functions Molecular mechanisms Reference ALL ALL cells/mice Oncogene Deferoxamine (DFO) inhibited the proliferation and growth of tumor cells and induced apoptosis in ALL cells by inactivating ROS/HIF-1α signaling. DFO/ROS/HIF-1α 92 BM samples of ALL patients/leukemia cell lines Oncogene Chemical inhibition of HIF-1α induced down-regulation of YY1, sensitizing cells to chemotherapeutic agents. HIF-1α/YY1 93 Human T-ALL cell samples/mice Oncogene HIF-1α KD restored the activity of mTOR at low oxygen concentrations, thereby regaining chemosensitivity in T-ALL cells. HIF-1α/mTOR 94 CLL lines/mice Oncogene SC could induce up-regulation of HIF-1α in CLL cells, ultimately promoting the survival of CLL cells. HIF-α/CXCL12/CXCR4 95 PB samples of CLL/cell lines/mice Oncogene In the TP53 -disrupted ( TP53 dis ) subset, the accumulation of HIF-1α led to reduced apoptosis and drug resistance in CLL cells when hypoxic. pVHL/HIF-1α 96 CLL patients/a murine model Oncogene The relevant drugs inhibited the growth of CLL cells by suppressing HIF-1α and interfering with intracellular redox homeostasis. HIF-1α/oxidative stress 97 Primary CLL cells/CLL cell lines/mice Oncogene EZN-2208, confirmed to inhibit HIF-1α, could increase the response to fludarabine by promoting apoptosis in CLL cells. EZN-2208/HIF-1α 98 AML AML patients/AML cells/mice Oncogene PARP14 induced the growth of AML cells and glycolysis via activating NF-κB and facilitating the expression of HIF-1α. PARP14/NF-κB/HIF-1α 99 Cell lines Oncogene Simvastatin inhibited the proliferation, migration, and invasion, and promoted apoptosis of AML cells by modulating the miR-19a-3p/HIF-1α axis. Simvastatin/miR-19a-3p/HIF-1α 45 THP-1 and HL-60 cells Oncogene Under hypoxia, CXCL2 promoted the proliferation and migration of AML cells by enhancing the activity of HIF-1α and up-regulating PIM2 expression. CXCL2/HIF-1α/PIM2, mTOR 100 AML cells Oncogene Inhibition of HIF-1α could down-regulate the expression of YAP in AML cells, thereby re-sensitizing AML cells to ADR in hypoxia. HIF-1α/YAP 101 AML patients/AML cell lines/mice Oncogene Echinomycin could effectively treat patients with TP53 -mutated AML via inhibiting HIF-1α. Echinomycin/HIF-1α 102 Healthy donor mesenchymal stromal cells/patient samples/AML cell lines Oncogene Abrogation of STC1 (stanniocalcin 1) or HIF-1α attenuated the inhibition of HSPC differentiation and proliferation by AML. HIF-1α/STC1 103 CML TKIs sensitive and resistant CML cells Oncogene HIF-1α could facilitate the expression of BCR-ABL1 and Met to rescue CML cells from death. HIF-1α/BCR-ABL1, Met 104 K-562 cells Oncogene 2-methoxyestradiol (2-ME2) induced apoptosis in CML cells by suppressing the expression of HIF-1α and down-regulating C-Myc or Bcl-xl and Bcl-2 genes. 2-ME2/HIF-1α/C-Myc, Bcl-xl or Bcl-2 105 CML patients/CML cell lines/mice Oncogene Tri-CAP (trident cold atmospheric plasma) could disrupt cancer survival pathways such as proliferative AKT/mTOR/HIF-1α signaling, thereby inducing apoptosis of tumor cells. Tri-CAP/AKT/mTOR/HIF-1α 106 lymphoma T-cell lymphoma cells Oncogene Sildenafil suppressed the expression of HIF-1α and decreased glucose metabolism, thus enhancing the killing ability of cisplatin on tumor cells. HIF-1α/glycolysis regulatory molecules/ROS 107 Mice Oncogene In in vivo experiments, MJ promoted T-cell lymphoma cell death by docking with prominent binding sites for HIF-1α, HK2, and Hsp70. MJ/HIF-1α 108 Tumor cell line Hut78/mice Oncogene Inhibition of HIF-1α blocked the glycolysis and IL-17 pathways induced by CHOP chemotherapy. HIF-1α/glycolysis/IL-17 109 MM MM cell lines Oncogene Macitentan down-regulated HIF-1α and the transcription and release of downstream pro-angiogenic cytokines, curbing the growth of MM cells. ET-1/HIF-1α/pro-angiogenic cytokines 110 MM patients/mice Oncogene Low expression of miR-411-3p could promote malignant proliferation and tumor stem cell-like properties of MM by activating HIF-1α. lncRNA ANRIL/miR-411-3p/HIF-1α 111 Abbreviations: DFO: Deferoxamine; mTOR: rapamycin; SC: stromal cell; BM: bone marrow; PB: peripheral blood; pVHL: von Hippel-Lindau tumor suppressor protein; YAP: yes-associated protein; ADR: adriamycin; 2-ME2: 2-Methoxyestradiol; MSCs: mesenchymal stromal cells; STC1: stanniocalcin 1; Tri-CAP: trident cold atmospheric plasma; PIM2: proviral integration moloney 2; ROS: reactive oxygen species; HK2: hexokinase 2; MJ: methyl jasmonate.

Acute lymphoblastic leukemia (ALL)

T-cell acute lymphoblastic leukemia (T-ALL) is a highly aggressive hematological malignancy. Based on the analysis of relevant experiments with T-ALL cells in vivo and in vitro , Fahy et al 94 revealed that hypoxia strongly suppresses the growth of CD45/CD7 T-ALL cells, which renders them insensitive to anti-leukemic drugs but retains their proliferative potential after the end of treatment. Further studies found that knockdown (KD) of HIF-1α counteracts the effects noted in hypoxic T-ALL and regains their chemosensitivity. Furthermore, activation of mammalian rapamycin (mTOR) was attenuated and drug resistance increased in hypoxic T-ALL cells; meanwhile, HIF-1α KD also restored mTOR activity at hypoxic concentrations and suppression of mTOR in HIF-1α KD T-ALL impaired the chemotherapeutic effect in leukemic cells. 94 Therefore, activation of the HIF-1α/mTORC1 axis under hypoxia can cause growth inhibition of leukemic cells, resulting in the development of drug resistance. Similarly, in another T-ALL study, Notch1 has been reported to function as an oncogenic player in the disease process. 112 Using small interfering RNA (siRNA) transfection, silencing HIF-1α suppressed Notch1 signaling under hypoxic conditions, as evidenced by reduced expression of its downstream target gene Hes1 , which inhibited cell proliferation, invasion, and chemoresistance; in contrast, silencing Notch1 did not affect the expression of HIF-1α. 112 Yin-Yang transcription factor 1 (YY1) is elevated in different cancers, including leukemia, and is negatively correlated with prognosis. 113 Importantly, the B-ALL cell line RS4;11 showed that both HIF-1α and YY1 proteins are co-expressed in response to hypoxia. Conversely, inhibition of HIF-1α expression levels triggered the down-regulation of YY1, resulting in increased sensitivity of tumor cells to chemotherapeutic agents. 93 In peripheral blood (PB) and BM samples from ALL patients, the researchers also observed a positive regulation of YY1 expression with HIF-1α. 93 Overall, these results provide the first evidence that YY1 can be transcriptionally modulated by HIF-1α to exert an oncogenic effect.

Chronic lymphocytic leukemia (CLL)

The HME of leukemia up-regulates HIF-1α and stimulates CLL cell survival and proliferation. In a previous study, Griggio et al 96 found that leukemia cells of CLL patient origin with TP53 (tumor suppressor gene) deficiency have higher expression and transcriptional activity of HIF-1α, which contributes to tumor progression, and therefore this group of patients is exposed to a worse prognosis. Consistently, they also observed that CLL cell lines cultured under hypoxia or co-cultured with stromal cells can further heighten the expression of HIF-1α. BAY87-2243 is a selective HIF-1α inhibitor that can effectively inhibit HIF-1α protein levels in tumor cells. 114 Evidence from both in vitro and in vivo experiments indicates that BAY87-2243 has anti-tumor effects and enhances the efficacy of fludarabine and ibrutinib in CLL, independent of functional TP53 . 114 Hence, Seiffert concluded that CLL cells whose TP53 was destroyed by HIF-1α inhibition are sensitive to fludarabine therapy. HIF-1α is also a novel modulator of CLL cell-TME interactions. In CLL cells, HIF-1α can regulate the expression of chemokine receptors and cell adhesion molecules, which in turn govern the interaction of cancer cells with the BM and spleen microenvironment. 115 In a mouse model of CLL, the researchers also demonstrated that inactivation of HIF-1α attenuates the chemotaxis and adhesion of leukemic cells to the stroma, reduces their colonization of the BM and spleen, and potentially prolongs the survival of mice. 115 In another study, hypoxia-mediated overexpression of HIF-1α increased the production and signaling of adenosine as well as protecting against drug-driven apoptosis in CLL cells, thus ultimately facilitating tumor progression. 116 However, blockade of the A2A adenosine receptor could abrogate the effects of HIF-1α in tumor cells, allowing leukemic cells to regain sensitivity to therapeutic agents. 116 Explicitly, targeting HIF-1α or its downstream regulatory pathways ( e.g. , CXCL12/CXCR4 axis) at the tumor and stromal cell levels may be a viable strategy to surmount HME-mediated protection of CLL cells. 95

Acute myeloid leukemia (AML)

In AML, leukemic stem cells (LSCs) can favor the constant renewal of tumor cells, leading to suffering from chemoresistance and a high relapse rate in treated patients, with a poor prognosis for the majority of patients. 101 , 117 In the current study, Zhu et al 101 concluded that overexpression of HIF-1α decreased the sensitivity of AML cells to adriamycin (ADR) under hypoxia and assisted in maintaining ADR resistance. However, the HIF-1α inhibitor CdCl2 remarkably inhibited the proliferation of AML cells by restoring their sensitivity to ADR in the presence of hypoxia. Further studies indicated that induction of HIF-1α significantly elevates the expression of yes-associated protein (YAP) in AML cells, and more markedly in drug-resistant cells. 101 Targeting the HIF-1α/YAP regulatory loop could effectively improve the efficacy of ADR-based AML chemotherapy. In the BM microenvironment, HIF-1α can up-regulate the expression of the AML-derived macrophage migration inhibitory factor MIF, thereby facilitating the proliferation and survival of AML cells. 118 Functionally, inhibition of MIF or HIF-1α in vivo significantly attenuated the tumor burden in the BM and prolonged the lifespan of AML mouse models. 118

Acute promyelocytic leukemia (APL) belongs to a class of AML characterized by the oncogenic fusion protein PML-RARα generated by the t (15;17) chromosome translocation. In APL, HIF-1α can act in concert with PML-RARα to function as a transcriptional co-activator. 119 In in vitro and in vivo studies, it has been identified that PML-RARα boosts pro-leukemic functions driven by HIF-1α, including cell migration, BM neo-angiogenesis, and self-renewal of tumor cells. In contrast, deletion of HIF-1α in APL cells dramatically impaired the migration, chemotaxis, and invasion of leukemic cells. 119 In AML, TP53 mutation predicts a poor prognosis for the disease. In another study, Wang et al 102 revealed that the HIF-1α inhibitor echinomycin significantly suppressed the proliferation of TP53 -mutated AML stem cells. Furthermore, they observed that echinomycin monotherapy proved to be more effective in killing AML cells than conventional combination chemotherapy (cytarabine plus daunorubicin) via the establishment of a mouse model of TP53 -mutated AML. 102 In addition, a clinical study demonstrated that HIF-1α is highly expressed in the BM of AML patients; however, when treated with evofosfamide (TH-302), the expression level of HIF-1α was notably decreased. 120 As discussed above, HIF-1α plays an essential oncogenic role in the development of AML. Surprisingly, in some of the examined models, the deficiency of HIF-1α causes a more rapid progression of AML. 121 , 122 For instance, repression of HIF-1α in an MLL-AF9 -driven mouse model of AML did not ameliorate the efficacy of chemotherapy and instead may contribute to disease progression. 121 Hence, these findings imply that the role of HIF-1α needs to be prudently considered in practical applications depending on the specific circumstances.

Chronic myeloid leukemia (CML)

The oncogenic fusion gene BCR-ABL is one of the crucial molecular biological features that are responsible for the pathogenesis and therapeutic resistance of CML patients and activates diverse signaling pathways related to the proliferation and survival of tumor cells, such as the JAK/STAT pathway. 123 Currently, tyrosine kinase inhibitors (TKIs) [ e.g. , imatinib (IM)] have been proven to be effective in the treatment of CML. 123 , 124 In 2010, Zhao et al 125 observed that in the absence of BCR-ABL drug resistance mutations, HIF-1α can stimulate higher levels of BCR-ABL expression in CML cell lines, leading to leukemic cells exhibiting enhanced resistance to IM. Mechanistically, HIF-1α up-regulates the expression level of BCR-ABL by accelerating the rate of glycolysis and therefore functions as an essential anti-drug factor. 125 Significantly, oxythiamine is capable of inhibiting HIF-1α-induced glycolysis, which in turn enhances the sensitivity of tumor cells to drugs. 125 Similarly, in the CML cell line K562, HIF-1α could strengthen the invasiveness of cancer cells by elevating the level of glycolysis in response to the knockdown of fumarate hydratase (FH) expression, while also entailing a reduced ability to repair DNA after damage. 126 Under this dual effect, the function of FH is disrupted and contributes to disease progression in CML. 126 Additionally, Siah2 is highly expressed in K562-IM-resistant cells (K562-R cells). 127 Vitamin K3 (a Siah2 inhibitor) improves the chemosensitivity of CML cells in the HME via targeted inhibition of the Siah2-PHD3-HIF-1α-VEGF axis. 127 On the other hand, curcumin directly represses the activity of HIF-1α and interferes with the metabolic mechanisms of tumor cells. 124 The combination of both with TKIs may potentiate the efficacy of IM. In BM specimens from CML patients, the expression level of HIF-1α mRNA was markedly higher than that of healthy controls. 128 Consistently, in in vitro experiments, HIF-1α deficiency down-regulated mRNA and protein expression in p21 and p53 in K562 cells, culminating in the suppression of CML cell proliferation. 128

The role of HIF-1α in lymphoma

Diffuse large B-cell lymphoma (DLBCL) is the most frequently aggressive form of non-Hodgkin's lymphoma (NHL), accounting for approximately 30% of all NHL. 129 Previous studies have shown that HIF-1α is stably expressed in most DLBCL patients. 130 One study examined the expression levels of HIF-1α protein in 153 patients with DLBCL treated sequentially with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or rituximab-CHOP (R-CHOP), and the results indicated that HIF-1α is correlated with the outcomes of DLBCL patients. 130 In the R-CHOP group, progression-free survival (PFS) and overall survival (OS) were dramatically superior in patients with low HIF-1α expression than in those with high HIF-1α expression, while there was no survival difference in CHOP-treated patients. 130 This finding highlights that HIF-1α is a critical prognostic factor in evaluating the likelihood of survival in DLBCL patients treated with R-CHOP. Moreover, the expression of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is elevated in NHL cell lines. 131 Indeed, GAPDH activates NF-κB signaling by interacting with tumor necrosis factor receptor-associated factor-2 (TRAF2) and further potentiates the transcription and activity of HIF-1α factor, leading to increased aggressiveness and angiogenesis of tumors. In addition, the study has reported that elevated levels of GAPDH mRNA expression in biopsied tissues from DLBCL patients similarly can induce high levels of HIF-1α, VEGF-A, etc . 131

Apart from the above, accumulating evidence has shown that HIF-1α remains dominant in the pathogenesis of other types of lymphoma. In Hodgkin's lymphoma (HL) cells, HIF-1α is predominantly expressed in the hypoxic side population (SP). 132 Under normoxia, the production of hydrogen peroxide in HL cell lines induces cell differentiation into the major population (MP) (with giant Hodgkin and Reed-Sternberg like cells), whereas the HIF-1α stabilizer, CoCl2, counteracts the effects of hydrogen peroxide. Further studies found that heme oxygenase-1 (HO-1), triggered by HIF-1α, scavenges intracellular ROS from SP and inhibits the differentiation of tumor cells, leaving patients with a poor prognostic outcome. 132 In in vivo experiments of mice, methyl jasmonate (MJ) promotes the death of T-cell lymphoma cells by binding to the action sites of HIF-1α, hexokinase 2, and Hsp70. Furthermore, MJ can relieve the chemoresistance role of HIF-1α on lymphoma cells in in vitro experiments. 108 Primary effusion lymphoma (PEL) is an aggressive B-cell lymphoma due to the infection of Kaposi's sarcoma-associated herpesvirus (KSHV). 133 Specifically, KSHV infection increases the activity of HIF-1α, which in turn activates the KSHV-encoded oncogene and maintains the optimal growth and metabolic state of PEL. 133 Using the virus-negative Burkitt’s lymphoma cell line BJAB, which does not express HIF-1α under normoxic conditions, as a control, HIF-1α in the PEL cell lines BCBL-1 and BC-3 could remarkably affect the growth metabolism, viral replication, and expression of viral-encoded oncogenes in PEL cells. 133 Thus, these results reflect that HIF-1α exerts an influential role in the PEL.

The role of HIF-1α in multiple myeloma (MM)

In MM cells, the endothelin-1 (ET-1) receptor, by binding to autocrine ET-1, can act to prolong the survival of tumor cells. 110 In essence, ET-1-mediated expression of HIF-1α prominently affects the release of pro-angiogenic cytokines ( e.g. , VEGF-A, IL-8, and ET-1 itself), thereby triggering the proliferation, invasion, and extramedullary metastasis of MM cells ( e.g. , RPMI-8226). Upon treatment with macitentan, a dual ET-1 receptor antagonist, Russignan et al 110 found that HIF-1α expression is down-regulated and reverses the effects of ET-1. More importantly, macitentan was equally effective in inhibiting the proliferation and microvascular density of tumor cells in animal experiments. Multidrug resistance is commonly associated with poor prognosis in MM patients. In an in vitro study, a single and combined treatment of MM cell lines RPMI8226/L-PAM and ARH-77/L-PAM with MEK inhibitors, PI3K inhibitors, and NF-κB inhibitors induced melphalan sensitization and markedly down-regulated the expression of HIF-1α. 134 Further studies revealed that RPMI8226/L-PAM resistance to melphalan was correlated with the activation of ERK1/2, Akt, and NF-κB to entail the up-regulation of HIF-1α, which consequently transcriptionally activates the target gene Survivin and decreases the expression of Bim. 134 In summary, these findings demonstrate that targeting HIF-1α, ERK1/2, Akt, and NF-κB has the potential to be used in the treatment of drug-resistant MM. Consistently, overexpression of tripartite motif-containing 44 (TRIM44) in MM cells is also crucial for treatment resistance in MM patients. 135 In a MM xenograft mouse model, the deubiquitinase TRIM44 promotes the quiescence of stem cancer cells; on the other hand, TRIM44 can spur the proliferation and survival of MM cells under hypoxia via elevating the expression level of HIF-1α, which ultimately exerts a drug-resistant and oncogenic effect. 135

The role of HIF-1α in cancer stem cells (CSCs)

CSCs, also known as tumor-initiating cells, are a subpopulation of tumor cells that exhibit properties similar to those of normal stem cells. 136 In most cases, subpopulations of CSCs have appeared in response to the accumulation of epigenetic and/or genetic alterations in normal stem cells or cancer cells. 137 It has been reported that cancer cells transfected with OCT3/4, SOX2, KLF4, and c-Myc can be transformed into CSCs. 138 The presence of CSCs in AML was first confirmed by Bonnet and Dick in 1997. 139 Subsequently, Al-Hajj et al revealed that the first CSCs observed in solid tumors were found in breast cancer in 2003. 140 Since then, numerous studies have indicated the presence of CSCs in solid tumors of many tissue types, including breast, 82 liver, 141 colorectum, 86 brain, etc.

It is currently well known that the core features of CSCs contain tumorigenicity and self-renewal, as well as drug resistance to chemotherapeutic agents. 137 Oxygen is an important regulator of cellular metabolism, and HIFs modulate cellular metabolic processes in a hypoxic environment. 137 As mentioned below, there is growing evidence that HIFs may exert a critical influence on the maintenance and evolution of CSCs. In hypoxia, the activation of HIF-1α not only augmented the number of cluster of differentiation (CD)133-positive glioma stem cells but also potentiated the stemness phenotype of cell lines. 142 The latter highlighted the expansion of tumor cells that harbor the surface markers CXCR4 (CD184), CD44 (low), and A2B5 in gliomas. 143 In addition, HIFs induce the self-renewal ability of glioblastoma CSCs and suppress their differentiation. 144 The effects of hypoxia are mediated by HIF-1α, but not by HIF-2α, 145 and are closely linked to the activity of NANOG protein in breast cancer stem cells (BCSC). 82 A key mechanism for BCSC enrichment is the recruitment of NANOG by HIF-1α to synergistically activate transcription of the TERT gene, which maintains telomere length and is required for stem cell self-renewal. 82 Conversely, NANOG itself can also stimulate the transcriptional activity of HIF-1α, serving as positive feedback. ELK3 (Net/SAP-2/Erp), a transcription factor activated by the Ras/extracellular signal-regulated kinase (ERK) signaling pathway, plays an important role in various physiological processes, including cell migration, invasion, angiogenesis, and tumorigenesis. 141 In 2017, Lee et al 141 isolated liver cancer stem cells (LCSCs) that expressed CD133 and CD44 from Huh7 HCC cells. They found that ELK3 expression was up-regulated in CD133 + /CD44 + LCSCs compared to non-CD133 + /CD44 + cells; mechanistically, the overexpression of ELK3 increased the metastatic potential of LCSCs by modulating HIF-1α expression. 141 The activity of HIFs can facilitate the phenotype of stem cells and increase the number of leukemic stem cells (LSCs) in the BM. 146 In AML, HIF-1α is overexpressed and selectively activated in the CD34 + /CD38 − subpopulation. 147 In lung cancer, CD133 expression induced by hypoxia was correlated with the binding of OCT4 and SOX2 to the PROM1 promoter. 148 Meanwhile, another recent study indicated that chronic intermittent hypoxia (CIH) promotes the migration, invasion, and stem cell-like properties of lung cancer cells via the HIF-1α/ATAD2 pathway. 149 In colorectal cancer cells, the expression of CD44 and OCT4 stem cell markers was reduced upon HIF-1α KD. 150 The expression of CD24 is highly triggered by hypoxia in human bladder cancer cell lines. 151 Moreover, co-immunostaining for HIF-1α and CD24 exhibited a statistically significant association in human urothelial carcinoma samples. 151

HIF-1α inhibitors and target therapy for tumors

As stated above, HIF-1α is tightly related to angiogenesis, immune escape, as well as the development, metastasis, invasion, and poor prognosis of tumors. Herein, it is critical to further strengthen the relevant studies on HIF-1α and its inhibitors for the understanding and treatment of tumors. To date, several HIF-1α inhibitors are already undergoing clinical trials for oncology treatment, with the underlying mechanisms of action including reduction of HIF-1α transcriptional activity, inhibition of HIF-1α expression, and induction of HIF-1α degradation.

Reduction of HIF-1α transcriptional activity

Minnelide, a precursor drug to regenerolactone, targets p300 and HSP70 and consequently restricts the transcriptional activity of HIF-1α to treat patients with recurrent pancreatic cancer. 152 It has been reported that PX-478 could hinder the transcriptional level of HIF-1α and inhibit translation by relying on VHL- and p53-independent mechanisms 153 ; the RNA antagonist EZN-2968 inhibited the production of mRNA product for HIF-1α. It is well known that PX-478 and EZN-2968 are dose-dependent drugs that reduce the secretion of HIF-1α and VEGF and cause tumor shrinkage in xenograft animal models, and that satisfactory results were obtained in phase I clinical trials. 154 , 155 Echinomycin, a small molecule antibiotic isolated from a streptomycete, is a potent small molecule inhibitor of HIF-1 that competitively inhibits the activity of HIF-1α by binding specifically to the HRE sequence. In several phases I/II clinical trials in solid tumors, echinomycin has been proven to be toxic and ineffective in the trials and therefore clinical studies were discontinued. Currently, the development of liposomal echinomycin could increase the accessibility and safety of the drug and inhibit the growth and metastasis of tumors. 156 Hence, a suitable drug formulation could provide a safe and effective therapeutic approach. Topotecan is a topoisomerase inhibitor that can suppress the aggregation of HIF-1α, thereby preventing the ribosomes of HIF-1α mRNA from reaching the binding site to interfere with transcription. 157 Similarly, YC-1 could inhibit the transcriptional activity of HIF-1α and even the accumulation of proteins. 158

Inhibition of HIF-1α expression

EZN-2208 (an irinotecan-modified drug), which can down-regulate the expression of HIF-1α by inhibiting topoisomerase, has been performed in different types of solid tumors; currently, it is being applied in preclinical studies and phase I clinical trials in neuroblastoma. 98 In preclinical studies, the nanoparticle–drug conjugate CRLX101 at chronic low doses together with BEV reduced BEV-induced up-regulation of HIF-1α and generated synergistic effects with minimal toxicity in mice. 159 However, it failed to demonstrate its anti-cancer role in early clinical trials 160 owing to its limited clinical activity. On the other hand, Mo et al 161 revealed that nickel nanoparticles (Nano-Ni) induce cell malignant transformation via activating the HIF-1α/miR-210/Rad52 pathway, which is involved in DNA damage and DNA repair defect. The utilization of Hsp90 inhibitors (1 μM of 17-AAG, an indirect HIF-1α inhibitor) or KD of HIF-1α attenuated the genotoxic and oncogenic effects of cells by inhibiting the nuclear accumulation of HIF-1α. 161

Induction of HIF-1α degradation

As a specific inhibitor of histone methyltransferase G9a, BIX01294 could improve the expression of PHD2 and pVHL (von Hippel-Lindau tumor suppressor protein), thereby promoting the hydroxylation and degradation of HIF-1α, which in turn triggers cell apoptosis and inhibits the proliferation, migration, and invasion of HCC cells. 162 Additionally, vorinostat, which augments the degradation of HIF-1α with the inhibition of histone dehydrogenase 9, is presently approved by the United States (US) FDA for the treatment of cutaneous T-cell lymphoma. 163 In vitro studies revealed that the HIF-1α inhibitor IDF-11774 inhibited the proliferation, migration, and invasion of tumor cells by promoting the degradation of HIF-1α. 164 Further investigations are needed to determine its clinical applicability.

Conclusion and perspectives

In recent years, with the development of cellular immunotherapy and molecular targeted therapy, the therapeutic effect of malignant tumors has markedly improved, but recurrence and drug resistance remains the main cause of death in multiple malignancies. Mechanistically, the adaptation to the HME is a key procedure in the development of most tumors. Hypoxic TME facilitates tumorigenesis, proliferation, and metastasis through underlying mechanisms such as promoting cell proliferation, inhibiting apoptosis, increasing angiogenesis, and boosting cellular immune escape. Indeed, mounting evidence has highlighted the important role of HIF-1α in tumors as the incidence of tumors is increasing, opening a novel avenue for the research of tumor pathogenesis and treatment. It has been observed that HIF-1α is highly expressed in most malignant tumor cells and engaged in inflammatory responses, tumorigenesis, and drug resistance under hypoxic conditions. Currently, a variety of HIF-1α inhibitors have been identified, but all are still at the preclinical or clinical research stage. However, many issues exist in the process of bringing these inhibitors to clinical applications, such as the use of HIF-1α inhibitors as monotherapy or in combination with radiotherapy and chemotherapy, and particularly exploring the efficacy and safety of different HIF-1α inhibitors in conjunction with immunotherapy. Therefore, it is rather essential to deeply understand the mechanism of HIF-1α-induced HME and tumor immune escape, and to find effective translational therapies for the early diagnosis of malignancies and to raise the cure rate as well as to prolong the survival of patients.

Author contributions

HP: study design. YD and CX: drafting of the manuscript. CY: critical revision of the manuscript. YZ: acquisition, assembly, analysis and interpretation of data, drafting of the manuscript, and critical revision of the manuscript.

Conflict of interests

The authors declare no conflict of interests.

Funding

This work was generously supported by the 10.13039/501100001809 National Natural Science Foundation of China (No. 82070175), the 10.13039/501100001809 Natural Science Foundation of Hunan Province (No. 2022JJ30830) and the Scientific Program of the Health Commission of Hunan Province (China) (No. 20201179).

References

1 Semenza G.L. Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy Trends Pharmacol Sci 33 4 2012 207 214 22398146 10.1016/j.tips.2012.01.005 PMC3437546

2 Wang G.L. Jiang B.H. Rue E.A. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O 2 tension Proc Natl Acad Sci U S A 92 12 1995 5510 5514 7539918 10.1073/pnas.92.12.5510 PMC41725

3 Lee J.W. Bae S.H. Jeong J.W. Hypoxia-inducible factor (HIF-1)alpha: its protein stability and biological functions Exp Mol Med 36 1 2004 1 12 15031665 10.1038/emm.2004.1

4 Levine A.J. Jenkins N.A. Copeland N.G. The roles of initiating truncal mutations in human cancers: the order of mutations and tumor cell type matters Cancer Cell 35 1 2019 10 15 30645969 10.1016/j.ccell.2018.11.009 PMC6376970

5 Rodriguez-Abreu D. Bordoni A. Zucca E. Epidemiology of hematological malignancies Ann Oncol 18 Suppl 1 2007 i3 i8 17311819 10.1093/annonc/mdl443

6 Adès L. Itzykson R. Fenaux P. Myelodysplastic syndromes Lancet 383 9936 2014 2239 2252 24656536 10.1016/S0140-6736(13)61901-7

7 Bhojwani D. Pui C.H. Relapsed childhood acute lymphoblastic leukaemia Lancet Oncol 14 6 2013 e205 e217 23639321 10.1016/S1470-2045(12)70580-6

8 Duca L. Cappellini M.D. Baronciani D. Non-transferrin-bound iron and oxidative stress during allogeneic hemopoietic stem cell transplantation in patients with or without iron overload Am J Hematol 93 9 2018 E250 E252 29981284 10.1002/ajh.25201

9 Najafi M. Majidpoor J. Toolee H. The current knowledge concerning solid cancer and therapy J Biochem Mol Toxicol 35 11 2021 e22900 10.1002/jbt.22900 34462987

10 Gilkes D.M. Semenza G.L. Wirtz D. Hypoxia and the extracellular matrix: drivers of tumour metastasis Nat Rev Cancer 14 6 2014 430 439 24827502 10.1038/nrc3726 PMC4283800

11 Rouault-Pierre K. Hamilton A. Bonnet D. Effect of hypoxia-inducible factors in normal and leukemic stem cell regulation and their potential therapeutic impact Expet Opin Biol Ther 16 4 2016 463 476 10.1517/14712598.2016.1133582 26679619

12 Ledford H. Callaway E. Biologists who decoded how cells sense oxygen win medicine Nobel Nature 574 7777 2019 161 162 31595071 10.1038/d41586-019-02963-0

13 Semenza G.L. Wang G.L. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation Mol Cell Biol 12 12 1992 5447 5454 1448077 10.1128/mcb.12.12.5447-5454.1992 PMC360482

14 Liu Z. Wu Z. Fan Y. An overview of biological research on hypoxia-inducible factors (HIFs) Endokrynol Pol 71 5 2020 432 440 33202030 10.5603/EP.a2020.0064

15 Korbecki J. Simińska D. Gąssowska-Dobrowolska M. Chronic and cycling hypoxia: drivers of cancer chronic inflammation through HIF-1 and NF-κB activation: a review of the molecular mechanisms Int J Mol Sci 22 19 2021 10701 10.3390/ijms221910701 PMC8509318 34639040

16 Tanaka T. Wiesener M. Bernhardt W. The human HIF (hypoxia-inducible factor)-3alpha gene is a HIF-1 target gene and may modulate hypoxic gene induction Biochem J 424 1 2009 143 151 19694616 10.1042/BJ20090120

17 Zhang P. Yao Q. Lu L. Hypoxia-inducible factor 3 is an oxygen-dependent transcription activator and regulates a distinct transcriptional response to hypoxia Cell Rep 6 6 2014 1110 1121 24613356 10.1016/j.celrep.2014.02.011

18 Yang S.L. Wu C. Xiong Z.F. Progress on hypoxia-inducible factor-3: its structure, gene regulation and biological function (Review) Mol Med Rep 12 2 2015 2411 2416 25936862 10.3892/mmr.2015.3689

19 Luo W. Hu H. Chang R. Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1 Cell 145 5 2011 732 744 21620138 10.1016/j.cell.2011.03.054 PMC3130564

20 Dengler V.L. Galbraith M.D. Espinosa J.M. Transcriptional regulation by hypoxia inducible factors Crit Rev Biochem Mol Biol 49 1 2014 1 15 24099156 10.3109/10409238.2013.838205 PMC4342852

21 Lee J.S. Kim E.Y. Iwabuchi K. Molecular and functional characterization of aryl hydrocarbon receptor nuclear translocator 1 (ARNT1) and ARNT2 in chicken ( Gallus gallus ) Comp Biochem Physiol C Toxicol Pharmacol 153 3 2011 269 279 21134488 10.1016/j.cbpc.2010.11.005

22 Reyes H. Reisz-Porszasz S. Hankinson O. Identification of the Ah receptor nuclear translocator protein (Arnt) as a component of the DNA binding form of the Ah receptor Science 256 5060 1992 1193 1195 1317062 10.1126/science.256.5060.1193

23 Ke Q. Costa M. Hypoxia-inducible factor-1 (HIF-1) Mol Pharmacol 70 5 2006 1469 1480 16887934 10.1124/mol.106.027029

24 Erbel P.J.A. Card P.B. Karakuzu O. Structural basis for PAS domain heterodimerization in the basic helix–loop–helix–PAS transcription factor hypoxia-inducible factor Proc Natl Acad Sci U S A 100 26 2003 15504 15509 14668441 10.1073/pnas.2533374100 PMC307597

25 Chapman-Smith A. Lutwyche J.K. Whitelaw M.L. Contribution of the Per/Arnt/Sim (PAS) domains to DNA binding by the basic helix-loop-helix PAS transcriptional regulators J Biol Chem 279 7 2004 5353 5362 14638687 10.1074/jbc.M310041200

26 Albadari N. Deng S. Li W. The transcriptional factors HIF-1 and HIF-2 and their novel inhibitors in cancer therapy Expet Opin Drug Discov 14 7 2019 667 682 10.1080/17460441.2019.1613370 PMC6559821 31070059

27 Jiang B.H. Rue E. Wang G.L. Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1 J Biol Chem 271 30 1996 17771 17778 8663540 10.1074/jbc.271.30.17771

28 Huang L.E. Gu J. Schau M. Regulation of hypoxia-inducible factor 1alpha is mediated by an O 2 - dependent degradation domain via the ubiquitin-proteasome pathway Proc Natl Acad Sci U S A 95 14 1998 7987 7992 9653127 10.1073/pnas.95.14.7987 PMC20916

29 Jiang B.H. Zheng J.Z. Leung S.W. Transactivation and inhibitory domains of hypoxia-inducible factor 1alpha. Modulation of transcriptional activity by oxygen tension J Biol Chem 272 31 1997 19253 19260 9235919 10.1074/jbc.272.31.19253

30 Freedman S.J. Sun Z.Y.J. Poy F. Structural basis for recruitment of CBP/p300 by hypoxia-inducible factor-1 alpha Proc Natl Acad Sci U S A 99 8 2002 5367 5372 11959990 10.1073/pnas.082117899 PMC122775

31 Mahon P.C. Hirota K. Semenza G.L. FIH-1:a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity Genes Dev 15 20 2001 2675 2686 11641274 10.1101/gad.924501 PMC312814

32 Kaelin W.G. Ratcliffe P.J. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway Mol Cell 30 4 2008 393 402 18498744 10.1016/j.molcel.2008.04.009

33 Jaakkola P. Mole D.R. Tian Y.M. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O 2 - regulated prolyl hydroxylation Science 292 5516 2001 468 472 11292861 10.1126/science.1059796

34 Hon W.C. Wilson M.I. Harlos K. Structural basis for the recognition of hydroxyproline in HIF-1 alpha by pVHL Nature 417 6892 2002 975 978 12050673 10.1038/nature00767

35 Lando D. Peet D.J. Gorman J.J. FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor Genes Dev 16 12 2002 1466 1471 12080085 10.1101/gad.991402 PMC186346

36 Dames S.A. Martinez-Yamout M. De Guzman R.N. Structural basis for Hif-1 alpha/CBP recognition in the cellular hypoxic response Proc Natl Acad Sci U S A 99 8 2002 5271 5276 11959977 10.1073/pnas.082121399 PMC122759

37 Majmundar A.J. Wong W.J. Simon M.C. Hypoxia-inducible factors and the response to hypoxic stress Mol Cell 40 2 2010 294 309 20965423 10.1016/j.molcel.2010.09.022 PMC3143508

38 Kierans S.J. Taylor C.T. Regulation of glycolysis by the hypoxia-inducible factor (HIF): implications for cellular physiology J Physiol 599 1 2021 23 37 33006160 10.1113/JP280572

39 Ho P.C. Bihuniak J. MacIntyre A. Phosphoenolpyruvate is a metabolic checkpoint of anti-tumor T cell responses Cell 162 6 2015 1217 1228 26321681 10.1016/j.cell.2015.08.012 PMC4567953

40 Greer S.N. Metcalf J.L. Wang Y. The updated biology of hypoxia-inducible factor EMBO J 31 11 2012 2448 2460 22562152 10.1038/emboj.2012.125 PMC3365421

41 Tam S.Y. Wu V.W.C. Law H.K.W. Hypoxia-induced epithelial-mesenchymal transition in cancers: HIF-1α and beyond Front Oncol 10 2020 486 32322559 10.3389/fonc.2020.00486 PMC7156534

42 Choi Y.K. A positive circuit of VEGF increases Glut-1 expression by increasing HIF-1α gene expression in human retinal endothelial cells Arch Pharm Res (Seoul) 40 12 2017 1433 1442 10.1007/s12272-017-0971-5 29022192

43 Suzuki T. Minagawa S. Yamazaki T. Loss of hypoxia inducible factor-1α aggravates γδ T-cell-mediated inflammation during acetaminophen-induced liver injury Hepatol Commun 2 5 2018 571 581 29761172 10.1002/hep4.1175 PMC5944581

44 Chen T. Li K. Liu Z. WDR5 facilitates EMT and metastasis of CCA by increasing HIF-1α accumulation in Myc-dependent and independent pathways Mol Ther 29 6 2021 2134 2150 33601056 10.1016/j.ymthe.2021.02.017 PMC8178527

45 Tian H. Qiang T. Wang J. Simvastatin regulates the proliferation, apoptosis, migration and invasion of human acute myeloid leukemia cells via miR-19a-3p/HIF-1α axis Bioengineered 12 2 2021 11898 11908 34895042 10.1080/21655979.2021.1999552 PMC8809937

46 Peng D. Wu T. Wang J. microRNA-671-5p reduces tumorigenicity of ovarian cancer via suppressing HDAC5 and HIF-1α expression Chem Biol Interact 355 2022 109780 10.1016/j.cbi.2021.109780 34990588

47 Akil A. Gutiérrez-García A.K. Guenter R. Notch signaling in vascular endothelial cells, angiogenesis, and tumor progression: an update and prospective Front Cell Dev Biol 9 2021 642352 10.3389/fcell.2021.642352 PMC7928398 33681228

48 Kopan R. Ilagan M.X.G. The canonical Notch signaling pathway: unfolding the activation mechanism Cell 137 2 2009 216 233 19379690 10.1016/j.cell.2009.03.045 PMC2827930

49 Landor S.K.J. Lendahl U. The interplay between the cellular hypoxic response and Notch signaling Exp Cell Res 356 2 2017 146 151 28456549 10.1016/j.yexcr.2017.04.030

50 Misiorek J.O. Przybyszewska-Podstawka A. Kałafut J. Context matters: Notch signatures and pathway in cancer progression and metastasis Cells 10 2021 94 33430387 10.3390/cells10010094 PMC7827494

51 Amelio I. Mancini M. Petrova V. p53 mutants cooperate with HIF-1 in transcriptional regulation of extracellular matrix components to promote tumor progression Proc Natl Acad Sci U S A 115 46 2018 E10869 E10878 30381462 10.1073/pnas.1808314115 PMC6243248

52 Amelio I. Melino G. The p53 family and the hypoxia-inducible factors (HIFs):determinants of cancer progression Trends Biochem Sci 40 8 2015 425 434 26032560 10.1016/j.tibs.2015.04.007

53 Keith B. Johnson R.S. Simon M.C. HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression Nat Rev Cancer 12 1 2012 9 22 10.1038/nrc3183 PMC3401912 22169972

54 Xu K. Zhan Y. Yuan Z. Hypoxia induces drug resistance in colorectal cancer through the HIF-1α/miR-338-5p/IL-6 feedback loop Mol Ther 27 10 2019 1810 1824 31208913 10.1016/j.ymthe.2019.05.017 PMC6822233

55 Kilic M. Kasperczyk H. Fulda S. Role of hypoxia inducible factor-1 alpha in modulation of apoptosis resistance Oncogene 26 14 2007 2027 2038 17043658 10.1038/sj.onc.1210008

56 Feng J. Zhan J. Ma S. LRG1 promotes hypoxia-induced cardiomyocyte apoptosis and autophagy by regulating hypoxia-inducible factor-1α Bioengineered 12 1 2021 8897 8907 34643170 10.1080/21655979.2021.1988368 PMC8806971

57 Semba H. Takeda N. Isagawa T. HIF-1α-PDK1 axis-induced active glycolysis plays an essential role in macrophage migratory capacity Nat Commun 7 2016 11635 10.1038/ncomms11635 PMC4873978 27189088

58 Wang G. Li Y. Yang Z. ROS mediated EGFR/MEK/ERK/HIF-1α Loop Regulates Glucose metabolism in pancreatic cancer Biochem Biophys Res Commun 500 4 2018 873 878 29702094 10.1016/j.bbrc.2018.04.177

59 Hu Y. Mu H. Deng Z. The transcription factor TEAD4 enhances lung adenocarcinoma progression through enhancing PKM2 mediated glycolysis Cell Biol Int 45 10 2021 2063 2073 34196069 10.1002/cbin.11654

60 Desvergne B. Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism Endocr Rev 20 5 1999 649 688 10529898 10.1210/edrv.20.5.0380

61 Chatterjee A. Mondal P. Ghosh S. PPARγ regulated CIDEA affects pro-apoptotic responses in glioblastoma Cell Death Dis 1 2015 15038 10.1038/cddiscovery.2015.38 PMC4979534 27551468

62 Feng J. Dai W. Mao Y. Simvastatin re-sensitizes hepatocellular carcinoma cells to sorafenib by inhibiting HIF-1α/PPAR-γ/PKM2-mediated glycolysis J Exp Clin Cancer Res 39 2020 24 32000827 10.1186/s13046-020-1528-x PMC6993409

63 Peach C.J. Mignone V.W. Arruda M.A. Molecular pharmacology of VEGF-A isoforms: binding and signalling at VEGFR2 Int J Mol Sci 19 4 2018 1264 29690653 10.3390/ijms19041264 PMC5979509

64 Peng G. Liu Y. Hypoxia-inducible factors in cancer stem cells and inflammation Trends Pharmacol Sci 36 6 2015 374 383 25857287 10.1016/j.tips.2015.03.003 PMC4461458

65 Santio N.M. Koskinen P.J. PIM kinases: from survival factors to regulators of cell motility Int J Biochem Cell Biol 93 2017 74 85 29108877 10.1016/j.biocel.2017.10.016

66 Casillas A.L. Chauhan S.S. Toth R.K. Direct phosphorylation and stabilization of HIF-1α by PIM1 kinase drives angiogenesis in solid tumors Oncogene 40 32 2021 5142 5152 34211090 10.1038/s41388-021-01915-1 PMC8364516

67 Fang C. Dai L. Wang C. Secretogranin II impairs tumor growth and angiogenesis by promoting degradation of hypoxia-inducible factor-1α in colorectal cancer Mol Oncol 15 12 2021 3513 3526 34160138 10.1002/1878-0261.13044 PMC8637574

68 Sun G. Li Y. Peng Y. Identification of a five-gene signature with prognostic value in colorectal cancer J Cell Physiol 234 4 2019 3829 3836 30132881 10.1002/jcp.27154

69 Liu J.W. Yu F. Tan Y.F. Profiling of tumor microenvironment components identifies five stroma-related genes with prognostic implications in colorectal cancer Cancer Biother Radiopharm 37 10 2022 882 892 33085921 10.1089/cbr.2020.4118

70 Noman M.Z. Hasmim M. Lequeux A. Improving cancer immunotherapy by targeting the hypoxic tumor microenvironment: new opportunities and challenges Cells 8 9 2019 1083 31540045 10.3390/cells8091083 PMC6770817

71 Zhang H. Lu H. Xiang L. HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells Proc Natl Acad Sci U S A 112 45 2015 E6215 E6223 26512116 10.1073/pnas.1520032112 PMC4653179

72 Deng J. Li J. Sarde A. Hypoxia-induced VISTA promotes the suppressive function of myeloid-derived suppressor cells in the tumor microenvironment Cancer Immunol Res 7 7 2019 1079 1090 31088847 10.1158/2326-6066.CIR-18-0507 PMC6606337

73 Deng Z. Teng Y.J. Zhou Q. Shuyu pills inhibit immune escape and enhance chemosensitization in hepatocellular carcinoma World J Gastrointest Oncol 13 11 2021 1725 1740 34853646 10.4251/wjgo.v13.i11.1725 PMC8603453

74 Wei H. Xie A. Li J. PD-1 + CD4 T cell immune response is mediated by HIF-1α/NFATc 1 pathway after P. yoelii infection Front Immunol 13 2022 942862 10.3389/fimmu.2022.942862 PMC9449323 36091043

75 Lin C. Lai S.W. Shen C.K. Fenofibrate inhibits hypoxia-inducible factor-1 alpha and carbonic anhydrase expression through activation of AMP-activated protein kinase/HO-1/Sirt1 pathway in glioblastoma cells Environ Toxicol 36 12 2021 2551 2561 34520103 10.1002/tox.23369

76 Osada-Oka M. Kuwamura H. Imamiya R. Suppression of the doxorubicin response by hypoxia-inducible factor-1α is strictly dependent on oxygen concentrations under hypoxic conditions Eur J Pharmacol 920 2022 174845 10.1016/j.ejphar.2022.174845 35202675

77 Soni S. Padwad Y.S. HIF-1 in cancer therapy: two decade long story of a transcription factor Acta Oncol 56 4 2017 503 515 28358664 10.1080/0284186X.2017.1301680

78 Semenza G.L. Hypoxia-inducible factors in physiology and medicine Cell 148 3 2012 399 408 22304911 10.1016/j.cell.2012.01.021 PMC3437543

79 Semenza G.L. Targeting HIF-1 for cancer therapy Nat Rev Cancer 3 10 2003 721 732 13130303 10.1038/nrc1187

80 Schito L. Semenza G.L. Hypoxia-inducible factors: master regulators of cancer progression Trends Cancer 2 12 2016 758 770 28741521 10.1016/j.trecan.2016.10.016

81 Multhoff G. Vaupel P. Hypoxia compromises anti-cancer immune responses Adv Exp Med Biol 1232 2020 131 143 31893404 10.1007/978-3-030-34461-0_18

82 Lu H. Lyu Y. Tran L. HIF-1 recruits NANOG as a coactivator for TERT gene transcription in hypoxic breast cancer stem cells Cell Rep 36 13 2021 109757 10.1016/j.celrep.2021.109757 34592152

83 Song Z. Liu T. Chen J. HIF-1α-induced RIT1 promotes liver cancer growth and metastasis and its deficiency increases sensitivity to sorafenib Cancer Lett 460 2019 96 107 31247273 10.1016/j.canlet.2019.06.016

84 Feng W. Xue T. Huang S. HIF-1α promotes the migration and invasion of hepatocellular carcinoma cells via the IL-8-NF-κB axis Cell Mol Biol Lett 23 2018 26 29881400 10.1186/s11658-018-0077-1 PMC5984319

85 Zhang Y. Jiang L. Qin N. hCINAP is potentially a direct target gene of HIF-1 and is required for hypoxia-induced EMT and apoptosis in cervical cancer cells Biochem Cell Biol 99 2 2021 203 213 32830518 10.1139/bcb-2020-0090

86 Tang Y.A. Chen Y.F. Bao Y. Hypoxic tumor microenvironment activates GLI2 via HIF-1α and TGF-β2 to promote chemoresistance in colorectal cancer Proc Natl Acad Sci U S A 115 26 2018 E5990 E5999 29891662 10.1073/pnas.1801348115 PMC6042102

87 Huang K. Zhang X. Hao Y. Hypoxia tumor microenvironment activates GLI2 through HIF-1 α and TGF- β 2 to promote chemotherapy resistance of colorectal cancer Comput Math Methods Med 2022 2022 2032895 10.1155/2022/2032895 PMC8853797 35186110

88 Huang S. Qi P. Zhang T. The HIF-1α/miR-224-3p/ATG5 axis affects cell mobility and chemosensitivity by regulating hypoxia-induced protective autophagy in glioblastoma and astrocytoma Oncol Rep 41 3 2019 1759 1768 30569180 10.3892/or.2018.6929

89 Xiang Z. Deng X. He W. Treatment of malignant pleural effusion in non-small cell lung cancer with VEGF-directed therapy Ann Med 54 1 2022 1357 1371 35543207 10.1080/07853890.2022.2071977 PMC9103356

90 Jaidee R. Kongpetch S. Senggunprai L. Phenformin inhibits proliferation, invasion, and angiogenesis of cholangiocarcinoma cells via AMPK-mTOR and HIF-1A pathways Naunyn-Schmiedeberg’s Arch Pharmacol 393 9 2020 1681 1690 32383028 10.1007/s00210-020-01885-3

91 Gaudichon J. Jakobczyk H. Debaize L. Mechanisms of extramedullary relapse in acute lymphoblastic leukemia: reconciling biological concepts and clinical issues Blood Rev 36 2019 40 56 31010660 10.1016/j.blre.2019.04.003

92 You H. Wang D. Wei L. Deferoxamine inhibits acute lymphoblastic leukemia progression through repression of ROS/HIF-1 α , Wnt/ β -catenin, and p38MAPK/ERK pathways JAMA Oncol 2022 2022 8281267 10.1155/2022/8281267 PMC8885176 35237325

93 Antonio-Andres G. Martinez-Ruiz G.U. Morales-Martinez M. Transcriptional regulation of Yin-Yang 1 expression through the hypoxia inducible factor-1 in pediatric acute lymphoblastic leukemia Int J Mol Sci 23 3 2022 1728 35163649 10.3390/ijms23031728 PMC8835886

94 Fahy L. Calvo J. Chabi S. Hypoxia favors chemoresistance in T-ALL through an HIF1α-mediated mTORC1 inhibition loop Blood Adv 5 2 2021 513 526 33496749 10.1182/bloodadvances.2020002832 PMC7839374

95 Vitale C. Griggio V. Riganti C. Targeting HIF-1α regulatory pathways as a strategy to hamper tumor-microenvironment interactions in CLL Cancers 13 12 2021 2883 34207596 10.3390/cancers13122883 PMC8229189

96 Griggio V. Vitale C. Todaro M. HIF-1α is over-expressed in leukemic cells from TP53 -disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia Haematologica 105 4 2020 1042 1054 31289209 10.3324/haematol.2019.217430 PMC7109756

97 Yosifov D.Y. Idler I. Bhattacharya N. Oxidative stress as candidate therapeutic target to overcome microenvironmental protection of CLL Leukemia 34 1 2020 115 127 31300746 10.1038/s41375-019-0513-x

98 Valsecchi R. Coltella N. Magliulo D. EZN-2208 treatment suppresses chronic lymphocytic leukaemia by interfering with environmental protection and increases response to fludarabine Open Biol 10 5 2020 190262 10.1098/rsob.190262 PMC7276525 32397871

99 Zhu Y. Liu Z. Wan Y. PARP14 promotes the growth and glycolysis of acute myeloid leukemia cells by regulating HIF-1α expression Clin Immunol 242 2022 109094 10.1016/j.clim.2022.109094 35944879

100 Li L. Zhao L. Man J. CXCL2 benefits acute myeloid leukemia cells in hypoxia Int J Lab Hematol 43 5 2021 1085 1092 33793061 10.1111/ijlh.13512

101 Zhu B. Pan S. Liu J. HIF-1α forms regulatory loop with YAP to coordinate hypoxia-induced adriamycin resistance in acute myeloid leukemia cells Cell Biol Int 44 2 2020 456 466 31617641 10.1002/cbin.11246

102 Wang Y. Liu Y. Bailey C. Therapeutic targeting of TP53-mutated acute myeloid leukemia by inhibiting HIF-1α with echinomycin Oncogene 39 14 2020 3015 3027 32060420 10.1038/s41388-020-1201-z PMC7291851

103 Waclawiczek A. Hamilton A. Rouault-Pierre K. Mesenchymal niche remodeling impairs hematopoiesis via stanniocalcin 1 in acute myeloid leukemia J Clin Invest 130 6 2020 3038 3050 32364536 10.1172/JCI133187 PMC7260026

104 Tsubaki M. Takeda T. Matsuda T. Hypoxia-inducible factor 1α inhibitor induces cell death via suppression of BCR-ABL1 and Met expression in BCR-ABL1 tyrosine kinase inhibitor sensitive and resistant chronic myeloid leukemia cells BMB Rep 56 2 2023 78 83 36195570 10.5483/BMBRep.2022-0095 PMC9978365

105 Zhang Y. Chen H. Shen Y. Combined effects of 2-methoxyestradiol (hypoxia-inducible factor 1 α inhibitor) and dasatinib (a second-generation tyrosine kinase inhibitor) on chronic myelocytic leukemia cells J Immunol Res 2022 2022 6324326 10.1155/2022/6324326 PMC9071866 35528614

106 Guo B. Pomicter A.D. Li F. Trident cold atmospheric plasma blocks three cancer survival pathways to overcome therapy resistance Proc Natl Acad Sci U S A 118 51 2021 e2107220118 10.1073/pnas.2107220118 PMC8713761 34916286

107 Rawat S.G. Tiwari R.K. Jaiswara P.K. Phosphodiesterase 5 inhibitor sildenafil potentiates the antitumor activity of cisplatin by ROS-mediated apoptosis: a role of deregulated glucose metabolism Apoptosis 27 7 2022 606 618 35725975 10.1007/s10495-022-01741-0

108 Goel Y. Yadav S. Pandey S.K. Methyl jasmonate cytotoxicity and chemosensitization of T cell lymphoma in vitro is facilitated by HK 2, HIF-1α, and Hsp70: implication of altered regulation of cell survival, pH homeostasis, mitochondrial functions Front Pharmacol 12 2021 628329 10.3389/fphar.2021.628329 PMC7954117 33716751

109 Wang B. Li K. Wang H. Systemic chemotherapy promotes HIF-1α-mediated glycolysis and IL-17F pathways in cutaneous T-cell lymphoma Exp Dermatol 29 10 2020 987 992 32573814 10.1111/exd.14133

110 Russignan A. Dal Collo G. Bagnato A. Targeting the endothelin-1 receptors curtails tumor growth and angiogenesis in multiple myeloma Front Oncol 10 2020 600025 10.3389/fonc.2020.600025 PMC7820698 33489901

111 Wang M. Zhao H.Y. Zhang J.L. Dysregulation of LncRNA ANRIL mediated by miR-411–3p inhibits the malignant proliferation and tumor stem cell like property of multiple myeloma via hypoxia-inducible factor 1α Exp Cell Res 396 1 2020 112280 10.1016/j.yexcr.2020.112280 32961145

112 Zou J. Li P. Lu F. Notch1 is required for hypoxia-induced proliferation, invasion and chemoresistance of T-cell acute lymphoblastic leukemia cells J Hematol Oncol 6 2013 3 23289374 10.1186/1756-8722-6-3 PMC3544631

113 Antonio-Andrés G. Rangel-Santiago J. Tirado-Rodríguez B. Role of Yin Yang-1 (YY1) in the transcription regulation of the multi-drug resistance ( MDR1 ) gene Leuk Lymphoma 59 11 2018 2628 2638 29616858 10.1080/10428194.2018.1448083

114 Seiffert M. HIF-1α: a potential treatment target in chronic lymphocytic leukemia Haematologica 105 4 2020 856 858 32238465 10.3324/haematol.2019.246330 PMC7109720

115 Valsecchi R. Coltella N. Belloni D. HIF-1α regulates the interaction of chronic lymphocytic leukemia cells with the tumor microenvironment Blood 127 16 2016 1987 1997 26825709 10.1182/blood-2015-07-657056 PMC4946537

116 Serra S. Vaisitti T. Audrito V. Adenosine signaling mediates hypoxic responses in the chronic lymphocytic leukemia microenvironment Blood Adv 1 1 2016 47 61 29296695 10.1182/bloodadvances.2016000984 PMC5744057

117 Zhu B. Zhong W. Cao X. Loss of miR-31-5p drives hematopoietic stem cell malignant transformation and restoration eliminates leukemia stem cells in mice Sci Transl Med 14 629 2022 eabh2548 10.1126/scitranslmed.abh2548 35080912

118 Abdul-Aziz A.M. Shafat M.S. Sun Y. HIF1α drives chemokine factor pro-tumoral signaling pathways in acute myeloid leukemia Oncogene 37 20 2018 2676 2686 29487418 10.1038/s41388-018-0151-1

119 Coltella N. Percio S. Valsecchi R. HIF factors cooperate with PML-RARα to promote acute promyelocytic leukemia progression and relapse EMBO Mol Med 6 5 2014 640 650 24711541 10.1002/emmm.201303065 PMC4023886

120 Badar T. Handisides D.R. Benito J.M. Phase I study of evofosfamide, an investigational hypoxia-activated prodrug, in patients with advanced leukemia Am J Hematol 91 8 2016 800 805 27169385 10.1002/ajh.24415 PMC4946992

121 Velasco-Hernandez T. Soneji S. Hidalgo I. Hif-1α deletion may lead to adverse treatment effect in a mouse model ofMLL-AF9-driven AML Stem Cell Rep 12 1 2019 112 121 10.1016/j.stemcr.2018.11.023 PMC6335588 30595549

122 Velasco-Hernandez T. Hyrenius-Wittsten A. Rehn M. HIF-1α can act as a tumor suppressor gene in murine acute myeloid leukemia Blood 124 24 2014 3597 3607 25267197 10.1182/blood-2014-04-567065

123 Nehme R. Hallal R. El Dor M. Repurposing of acriflavine to target chronic myeloid leukemia treatment Curr Med Chem 28 11 2021 2218 2233 32900342 10.2174/0929867327666200908114411

124 Monteleone F. Taverna S. Alessandro R. SWATH-MS based quantitative proteomics analysis reveals that curcumin alters the metabolic enzyme profile of CML cells by affecting the activity of miR-22/IPO 7 /HIF-1α axis J Exp Clin Cancer Res 37 2018 170 30045750 10.1186/s13046-018-0843-y PMC6060558

125 Zhao F. Mancuso A. Bui T.V. Imatinib resistance associated with BCR-ABL upregulation is dependent on HIF-1alpha-induced metabolic reprograming Oncogene 29 20 2010 2962 2972 20228846 10.1038/onc.2010.67 PMC2874611

126 Li S. Qiao C. Yang L. Fumarate hydratase deficiency induces chronic myeloid leukemia progression Transl Cancer Res 8 2 2019 592 602 35116792 10.21037/tcr.2019.03.23 PMC8797861

127 Huang J. Lu Z. Xiao Y. Inhibition of Siah2 ubiquitin ligase by vitamin K3 attenuates chronic myeloid leukemia chemo-resistance in hypoxic microenvironment Med Sci Mon Int Med J Exp Clin Res 24 2018 727 735 10.12659/MSM.908553 PMC5810368 29400343

128 Chen H. Shen Y. Gong F. HIF-α promotes chronic myelogenous leukemia cell proliferation by upregulating p21 expression Cell Biochem Biophys 72 1 2015 179 183 25596666 10.1007/s12013-014-0434-2

129 Larouche J.F. Berger F. Chassagne-Clément C. Lymphoma recurrence 5 years or later following diffuse large B-cell lymphoma: clinical characteristics and outcome J Clin Oncol 28 12 2010 2094 2100 20308668 10.1200/JCO.2009.24.5860

130 Evens A.M. Sehn L.H. Farinha P. Hypoxia-inducible factor-1{alpha}expression predicts superior survival in patients with diffuse large B-cell lymphoma treated with R-CHOP J Clin Oncol 28 6 2010 1017 1024 20048181 10.1200/JCO.2009.24.1893 PMC2834428

131 Chiche J. Pommier S. Beneteau M. GAPDH enhances the aggressiveness and the vascularization of non-Hodgkin's B lymphomas via NF-κB-dependent induction of HIF-1α Leukemia 29 5 2015 1163 1176 25394713 10.1038/leu.2014.324

132 Nakashima M. Watanabe M. Nakano K. Differentiation of Hodgkin lymphoma cells by reactive oxygen species and regulation by heme oxygenase-1 through HIF-1α Cancer Sci 112 6 2021 2542 2555 33738869 10.1111/cas.14890 PMC8177765

133 Shrestha P. Davis D.A. Veeranna R.P. Hypoxia-inducible factor-1 alpha as a therapeutic target for primary effusion lymphoma PLoS Pathog 13 9 2017 e1006628 10.1371/journal.ppat.1006628 PMC5619862 28922425

134 Tsubaki M. Takeda T. Tomonari Y. Overexpression of HIF-1α contributes to melphalan resistance in multiple myeloma cells by activation of ERK1/2, Akt, and NF-κB Lab Invest 99 1 2019 72 84 30353128 10.1038/s41374-018-0114-8

135 Chen Z. Lin T.C. Bi X. TRIM44 promotes quiescent multiple myeloma cell occupancy and survival in the osteoblastic niche via HIF-1α stabilization Leukemia 33 2 2019 469 486 30089913 10.1038/s41375-018-0222-x PMC6365383

136 Clarke M.F. Dick J.E. Dirks P.B. Cancer stem cells: perspectives on current status and future directions: AACR Workshop on cancer stem cells Cancer Res 66 19 2006 9339 9344 16990346 10.1158/0008-5472.CAN-06-3126

137 Tong W.W. Tong G.H. Liu Y. Cancer stem cells and hypoxia-inducible factors (Review) Int J Oncol 53 2 2018 469 476 29845228 10.3892/ijo.2018.4417

138 Beck B. Blanpain C. Unravelling cancer stem cell potential Nat Rev Cancer 13 10 2013 727 738 24060864 10.1038/nrc3597

139 Bonnet D. Dick J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell Nat Med 3 7 1997 730 737 9212098 10.1038/nm0797-730

140 Al-Hajj M. Wicha M.S. Benito-Hernandez A. Prospective identification of tumorigenic breast cancer cells Proc Natl Acad Sci U S A 100 7 2003 3983 3988 12629218 10.1073/pnas.0530291100 PMC153034

141 Lee J.H. Hur W. Hong S.W. ELK3 promotes the migration and invasion of liver cancer stem cells by targeting HIF-1α Oncol Rep 37 2 2017 813 822 27959451 10.3892/or.2016.5293

142 Shi Q.Y. Zhang S.J. Liu L. Sevoflurane promotes the expansion of glioma stem cells through activation of hypoxia-inducible factors in vitro Br J Anaesth 114 5 2015 825 830 25492570 10.1093/bja/aeu402

143 Soeda A. Park M. Lee D. Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1alpha Oncogene 28 45 2009 3949 3959 19718046 10.1038/onc.2009.252

144 Zhang S. Luo X. Wan F. The roles of hypoxia-inducible factors in regulating neural stem cells migration to glioma stem cells and determining their fates Neurochem Res 37 12 2012 2659 2666 22991140 10.1007/s11064-012-0879-x

145 Semenza G.L. Regulation of the breast cancer stem cell phenotype by hypoxia-inducible factors Clin Sci (Lond) 129 12 2015 1037 1045 26405042 10.1042/CS20150451

146 Deynoux M. Sunter N. Hérault O. Hypoxia and hypoxia-inducible factors in leukemias Front Oncol 6 2016 41 26955619 10.3389/fonc.2016.00041 PMC4767894

147 Heddleston J.M. Wu Q. Rivera M. Hypoxia-induced mixed-lineage leukemia 1 regulates glioma stem cell tumorigenic potential Cell Death Differ 19 3 2012 428 439 21836617 10.1038/cdd.2011.109 PMC3229666

148 Sun J.C. He F. Yi W. High expression of HIF-2α and its anti-radiotherapy effect in lung cancer stem cells Genet Mol Res 14 4 2015 18110 18120 26782458 10.4238/2015.December.22.37

149 Hao S. Li F. Jiang P. Effect of chronic intermittent hypoxia-induced HIF-1α/ATAD2 expression on lung cancer stemness Cell Mol Biol Lett 27 2022 44 35672694 10.1186/s11658-022-00345-5 PMC9172155

150 Vadde R. Vemula S. Jinka R. Role of hypoxia-inducible factors (HIF) in the maintenance of stemness and malignancy of colorectal cancer Crit Rev Oncol Hematol 113 2017 22 27 28427511 10.1016/j.critrevonc.2017.02.025

151 Thomas S. Harding M.A. Smith S.C. CD24 is an effector of HIF-1-driven primary tumor growth and metastasis Cancer Res 72 21 2012 5600 5612 22926560 10.1158/0008-5472.CAN-11-3666 PMC3488144

152 Banerjee S. Saluja A. Minnelide, a novel drug for pancreatic and liver cancer Pancreatology 15 4 2015 S39 S43 26122306 10.1016/j.pan.2015.05.472 PMC4515388

153 Koh M.Y. Spivak-Kroizman T. Venturini S. Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1alpha Mol Cancer Therapeut 7 1 2008 90 100 10.1158/1535-7163.MCT-07-0463 18202012

154 Infantino V. Santarsiero A. Convertini P. Cancer cell metabolism in hypoxia: role of HIF-1 as key regulator and therapeutic target Int J Mol Sci 22 11 2021 5703 34071836 10.3390/ijms22115703 PMC8199012

155 Liu J. Zhang C. Zhao Y. Parkin targets HIF-1α for ubiquitination and degradation to inhibit breast tumor progression Nat Commun 8 1 2017 1823 29180628 10.1038/s41467-017-01947-w PMC5703960

156 Bailey C.M. Liu Y. Peng G. Liposomal formulation of HIF-1α inhibitor echinomycin eliminates established metastases of triple-negative breast cancer Nanomedicine 29 2020 102278 10.1016/j.nano.2020.102278 PMC7508926 32738299

157 Parmakhtiar B. Burger R.A. Kim J.H. HIF inactivation of p53 in ovarian cancer can be reversed by topotecan, restoring cisplatin and paclitaxel sensitivity Mol Cancer Res 17 8 2019 1675 1686 31088908 10.1158/1541-7786.MCR-18-1109

158 Hu H. Miao X.K. Li J.Y. YC-1 potentiates the antitumor activity of gefitinib by inhibiting HIF-1α and promoting the endocytic trafficking and degradation of EGFR in gefitinib-resistant non-small-cell lung cancer cells Eur J Pharmacol 874 2020 172961 10.1016/j.ejphar.2020.172961 32044322

159 Pham E. Birrer M.J. Eliasof S. Translational impact of nanoparticle-drug conjugate CRLX101 with or without bevacizumab in advanced ovarian cancer Clin Cancer Res 21 4 2015 808 818 25524310 10.1158/1078-0432.CCR-14-2810

160 Schmidt K.T. Peer C.J. Huitema A.D.R. Measurement of NLG207 (formerly CRLX101) nanoparticle-bound and released camptothecin in human plasma J Pharm Biomed Anal 181 2020 113073 10.1016/j.jpba.2019.113073 PMC7068816 31927166

161 Mo Y. Zhang Y. Zhang Y. Nickel nanoparticle-induced cell transformation: involvement of DNA damage and DNA repair defect through HIF-1α/miR-210/Rad52 pathway J Nanobiotechnol 19 2021 370 10.1186/s12951-021-01117-7 PMC8600818 34789290

162 Oh S.Y. Seok J.Y. Choi Y.S. The histone methyltransferase inhibitor BIX01294 inhibits HIF-1α stability and angiogenesis Mol Cell 38 6 2015 528 534 10.14348/molcells.2015.0026 PMC4469910 26013382

163 Li Y. Wang F. Chen X. Zinc-dependent deacetylase (HDAC) inhibitors with different zinc binding groups Curr Top Med Chem 19 3 2019 223 241 30674261 10.2174/1568026619666190122144949

164 Kim M.H. Lee T.H. Lee J.S. Hif-1α inhibitors could successfully inhibit the progression of differentiated thyroid cancer in vitro Pharmaceuticals 13 9 2020 208 32847004 10.3390/ph13090208 PMC7558478

Peer review under responsibility of Chongqing Medical University.